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Abstract 
Recent genome-wide association studies have identified five loci (BIN1, CLU, CR1, 
EXOC3L2 and PICALM) as genetic determinants of Alzheimer’s disease (AD). We attempted 
to confirm the association between these genes and the AD risk in three contrasting 
European populations (from Finland, Italy and Spain). Since CLU and CR1 had already been 
analyzed in these populations, we restricted our investigation to BIN1, EXO2CL3 and 
PICALM. In a total of 2,816 AD cases and 2,706 controls, we unambiguously replicated the 
association of rs744373 (for BIN1) and rs541458 (for PICALM) polymorphisms with the AD 
risk (OR=1.26, 95% CI [1.15-1.38], p=2.9x10-7, and OR=0.80, 95% CI [0.74-0.88], p=4.6x10-
7, respectively). In a meta-analysis, rs597668 (EXOC3L2) was also associated with the AD 
risk, albeit to a lesser extent (OR=1.19, 95% CI [1.06-1.32], p=2.0x10-3). However, this signal 
did not appear to be independent of APOE. 
In conclusion, we confirmed that BIN1 and PICALM are genetic determinants of AD, whereas 
the potential involvement of EXOC3L2 requires further investigation. 
 
Introduction 
Although Alzheimer's disease (AD) is the most common cause of dementia in the elderly, its 
aetiology is still not fully understood. The characterization of causative factors is thus 
important for better defining the pathophysiological processes involved. In this context, the 
identification of genes involved in monogenic forms of AD has significantly contributed to our 
knowledge of the disease mechanisms (Bettens, 2010). In contrast, the characterization of 
genetic factors involved in the common forms of AD (i.e. lacking classical Mendelian 
inheritance) has encountered significant difficulties; the apolipoprotein E (APOE) gene is the 
only globally valid genetic determinant of AD to have been unambiguously identified in 15 
years of intensive research (Lambert, 2007). 
However, as with other multifactorial diseases, this systematic inability to detect new genetic 
determinants has prompted more comprehensive investigations using genome-wide 
association studies (GWASs). We and others performed three large GWASs in this field and 
reported that the CLU (clusterin), PICALM (phosphatidylinositol binding clathrin assembly 
protein), CR1 (complement component [3b/4b] receptor 1), BIN1 (bridging integrator 1) and 
EXOC3L2 (exocyst complex component 3-like 2) loci were associated with the AD risk 
(Harold, 2009; Lambert, 2009; Seshadri, 2010). 
To help to clarify the relevance of these genes as genetic determinants of AD, we analyzed 
their associations in contrasting European populations from Finland (n=1,123), Italy 
(n=2,811) and Spain (n=1,588). Since CLU and CR1 have been already studied in these 
populations (Lambert, 2009), we only tested single-nucleotide polymorphisms (SNPs) within 
PICALM, BIN1 and EXOC3L2. 
 
Materials and Methods 
All clinical diagnoses of probable AD were established according to the DSM-III-R and 
NINCDS-ADRDA criteria. Controls were defined as subjects not meeting the DMS-III-R 
dementia criteria and with intact cognitive functions (MMS>25). Written, informed consent 
was obtained from study participants or, for those with substantial cognitive impairment, from 
a caregiver, legal guardian, or other proxy. The study protocols for all populations were 
reviewed and approved by the appropriate independent ethics committees in each country. 
Information on age and gender in the cases and controls included in the study are shown in 
Table 1. Samples with missing age or gender data were excluded, yielding a total of 2,816 
AD cases and 2,706 controls. 
Genotyping for the SNPs (rs744373 in BIN1, rs597668 in EXOC3L2 and rs541458 in 
PICALM) was performed with a Taqman system (Applied Biosystems). The primer and probe 
sequences are available on request. In order to avoid bias, cases and controls were 
randomly mixed when genotyping and the laboratory personnel were blinded to case/control 
status. The genotyping success rate was at least 95% and no departure from Hardy-
Weinberg equilibrium was observed for the markers (Table 2). 
We undertook logistic regression analyses in each country (Finland, Italy and Spain) using 
an additive genetic model which took account of age, gender, disease status and (when 
necessary) centre. All analyses were performed with SAS software (release 9.1, SAS 
Institute, Cary, NC, USA). We then used inverse-variance weighting (also known as fixed-
effects meta-analysis) with adjustments for age and gender for the overall effect assessment, 
using Review Manager software (release 5.0). Interactions between BIN1, EXOC3L2, 
PICALM and APOE ε4 polymorphisms were tested in logistic regression models adjusted for 
age, gender and (when necessary) centre. We again used inverse-variance weighting, with 
adjustments for age and gender for assessment of the overall interaction. Linkage 
disequilibrium was assessed using Haploview software. 
 
Results 
In each data set, we evaluated the association of AD with the rs744373, rs597668 and 
rs541458 SNPs within the BIN1, EXOC3L2 and PICALM loci, respectively. Even though the 
detected associations were not always statistically significant in all data sets, they were 
comparable in direction in the three different European populations. When the data sets were 
examined in a meta-analysis, we found strong evidence of associations for BIN1 (OR=1.26, 
p=2.9x10-7), PICALM (OR=0.80, p=4.7x10-7) and, to a lesser extent, EXOC3L2 (OR=1.19, 
p=2.0x10-3) (Table 3). 
We also searched for significant interactions between these three loci and APOE but failed to 
identify any in either the independent data sets or in the meta-analysis. We nevertheless re-
evaluated the association of the BIN1, PICALM and EXOC3L2 SNPs with the AD risk by 
adjusting for age, gender and the presence of at least one APOE ε4 allele. Whereas the 
BIN1 and PICALM associations were not modified (data not shown), we found no evidence 
of an association of EXOC3L2 with the AD risk after adjustment of the data sets taken 
individually (Finland, OR=0.91, p=4.2x10-1; Italy, OR=0.99, p=8.9x10-1; Spain, OR=1.06, 
p=6.2x10-1) or in the meta-analysis (OR=0.98, p=7.8x10-1). 
 
Discussion 
Over recent months, our picture of the genetics of AD has changed greatly and suggests that 
most of the genuine genetic determinants of this disease will differ from those suspected 
before the advent of the GWASs (Laumet, 2010; Sleegers, 2010). By looking at contrasting 
European populations of AD cases and controls in which the associations of CLU and CR1 
with AD had already replicated (Lambert, 2009), we confirmed the association of PICALM 
and BIN1 with the AD risk. The ORs are comparable in direction and magnitude with those 
originally reported. The association of PICALM with the AD risk has been already replicated 
in several large data sets (Carrasquillo, 2010; Corneveaux, 2010; Jun, in press; Kamboh, in 
press; Seshadri, 2010). Using the ORs reported in the AlzGene database 
(http://www.alzgene.org) (Bertram, 2007) and by including our new data, a meta-analysis 
unambiguously showed that this gene is a genuine risk factor for AD (OR=0.87, 95%CI [0.84-
0.90], p=5.5x10-18, p for heterogeneity=0.27). 
To the best of our knowledge, our study is the first to have replicated the association of the 
BIN1 and EXOC3L2 loci with the AD risk. The meta-analysis of our data and those gathered 
by Seshadri et al. strongly supported the involvement of the BIN1 gene in AD (OR=1.16, 
95%CI [1.12-1.21, p=1.6x10-15, p for heterogeneity=0.14). However, in contrast to Seshadri 
et al.'s report, we were unable to show that the EXOC3L2 signal was independent of the 
APOE locus. Surprisingly, and even though this gene locus is close to APOE, we did not 
detect linkage disequilibrium between the APOE ε4 allele and the rs597668 SNP (D’=0.36 
and r2=0.075 at most, in the Finland data set). This locus thus deserves more attention, in 
order to confirm or refute its association with the AD risk. 
In conclusion, we unambiguously replicated the association of the PICALM and BIN1 loci 
(both of which code for proteins involved in endocytosis and clathrin-mediated synaptic 
vessel formation (Harel, 2008; Wigge, 1997)) with the AD risk in contrasting European 
populations. In order to determine the exact implication of BIN1 and PICALM in AD, it is now 
essential to develop major, systematic, ambitious efforts in sequencing and genotyping (even 
for rare variants), together with replication in large, independent populations and functional 
analyses of intermediate phenotypes. 
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AD cases Controls AD cases controls AD cases controls
n 589 541 1 520 1 291 755 833
Mean age 71.3 ± 7.4 69.0 ± 6.4 76.6 ± 8.7 72.3 ± 8.9 75.3 ± 9.3 76.9 ± 10.9
Mean age at onset 71.3 ± 7.4 - 73.8 ± 8.8 - 72.5 ± 9.4 -
% male 32 42 32 45 43 38
Finland (1 centre) Spain (3 centres)Italy (10 centres)
Table 2: Genotype distribution of rs744373, rs597668 and rs541458 in AD cases and 
controls 
 
rs744373   Genotype distribution  freq. (n)   AA AG GG 
        
Finland        
Controls (529)  0.603 (319) 0.337 (178) 0.060 (32) 
Cases    (563)  0.572 (322) 0.368 (207) 0.060 (34) 
Italy        
Controls (1265)  0.535 (677) 0.399 (504) 0.066 (84) 
Cases    (1460)  0.489 (714) 0.431 (629) 0.080 (117) 
Spain        
Controls (829)  0.551 (457) 0.395 (327) 0.054 (45) 
Cases    (726)  0.463 (336) 0.423 (307) 0.114 (83) 
rs597668   Genotype distribution  freq. (n)   TT TC CC 
        
Finland        
Controls (529)  0.571 (302) 0.348 (184) 0.081 (43) 
Cases    (562)  0.471 (265) 0.429 (241) 0.100 (56) 
Italy        
Controls (1268)  0.773 (980) 0.210 (266) 0.017 (22) 
Cases    (1457)  0.765 (1115) 0.219 (336) 0.140 (90) 
Spain        
Controls (832)  0.804 (669) 0.180 (150) 0.016 (13) 
Cases    (727)  0.769 (559) 0.212 (54) 0.019 (14) 
rs541458   Genotype distribution  freq. (n)   TT TG GG 
        
Finland        
Controls (521)  0.403 (210) 0.430 (225) 0.167 (86) 
Cases    (561)  0.438 (246) 0.437 (245) 0.125 (70) 
Italy        
Controls (1257)  0.439 (552) 0.446 (561) 0.115 (144) 
Cases    (1460)  0.515 (752) 0.406 (592) 0.080 (116) 
Spain        
Controls (819)  0.492 (403) 0.419 (343) 0.089 (73) 
Cases    (723)  0.546 (395) 0.391 (283) 0.062 (45) 
 
Table 3: Association of rs744373, rs597668 and rs541458 with the AD risk in Finnish, Italian 
and Spanish case-control studies. (HW, hardy-Weinberg; MAF, minor allele Frequency) 
 
 
rs744373 HW APOE  interaction
(BIN1) Cases Controls Cases Controls OR (95% CI) P  value P value
   Finland 563 529 0.24 0.23 2.9x10-1 1.12 (0.92-1.37) 2.6x10-1 8.5x10-1
   Italy 1 460 1 265 0.30 0.27 4.5x10-1 1.22 (1.07-1.38) 2.0x10-3 6.6x10-1
   Spain 726 829 0.33 0.25 1.7x10-1 1.43 (1.22-1.68) 1.4x10-6 7.3x10-1
Meta-analysis1 1.26 (1.15-1.38) 2.9x10-7 6.8x10-1
rs597668 APOE  interaction
(EXO3CL2) Cases Controls Cases Controls OR (95% CI) P  value P value
   Finland 562 529 0.31 0.26 5.0x10-2 1.38 (1.14-1.66) 9.0x10-4 5.9x10-1
   Italy 1 457 1 268 0.13 0.12 4.2x10-1 1.05 (0.89-1.24) 5.7x10-1 6.3x10-2
   Spain 727 832 0.13 0.11 1.8x10-1 1.19 (0.96-1.48) 1.1x10-1 7.9x10-1
Meta-analysis1 1.19 (1.06-1.32) 2.0x10-3 1.1x10-1
rs541458 APOE  interaction
(PICALM) Cases Controls Cases Controls OR (95% CI) P  value P value
   Finland 561 521 0.34 0.38 6.0x10-2 0.85 (0.71-1.01) 6.8x10-2 9.0x10-1
   Italy 1 460 1 257 0.30 0.26 9.4x10-1 0.78 (0.69-0.88) 5.1x10-5 6.6x10-1
   Spain 723 819 0.26 0.30 1.0x10-1 0.81 (0.69-0.95) 1.1x10-2 7.1x10-1
Meta-analysis1 0.80 (0.74-0.88) 4.6x10-7 9.7x10-1
1 inverse-variance weighting  with adjustments for age, gender and centre when necessary 
A fixed effect model was used (p-value for heterogeinity not significant whatever the SNP analysed, 
p=0.12 for BIN1, p=0,11 for EXO2CL3 and p=0.68 for PICALM)
N MAF Association Test
N MAF Association Test
N MAF Association Test
